Latest Takeda Pharmaceutical Company Stories
Bernstein Liebhard LLP reports on a new study that provides further support regarding the link between Actos and bladder cancer. The study found an 83 percent increased risk of developing bladder cancer in those who took Actos, which increased to an 88 percent increased risk for those who took higher doses of the drug for a longer duration New York, New York (PRWEB) June 04, 2012 Bernstein Liebhard LLP, a nationwide law firm representing clients who have been injured by dangerous drugs...
DEERFIELD, Ill., and OSAKA, Japan, June 4, 2012 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and its wholly owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. (TPUSA), jointly announced that Takeda's wholly owned subsidiary, Takeda America Holdings, Inc., has completed its acquisition of URL Pharma, Inc. (URL Pharma) for an upfront payment of $800 million. The deal also includes an agreement for future performance-based contingent earn out payments. With the...
According to court documents, on May 14th, 2012, a Minnesota man, William Blumenstine, and his wife filed a lawsuit in Minnesota District Court (case no. 0:2012cv01162) alleging he suffered bladder cancer after taking Actos. Actos is a type 2 diabetes drug, manufactured by Takeda Pharmaceutical Industries Limited and promoted as decreasing insulin resistance. On April 9th 2012, US District Judge Rebecca Doherty, overseeing the Actos Multidistrict Litigation (MDL 2299) signed a Direct...
OSAKA, Japan, and SAO JERONIMO, Brazil, May 25, 2012 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") and Multilab Industria e Comercio de Produtos Farmaceuticos Ltda. (Rio Grande do Sul, Brazil, "Multilab") today jointly announced that both parties have signed an agreement whereby Takeda Farmaceutica Brasil Ltda. (Sao Paulo, Brazil, "Takeda Brazil"), a wholly-owned subsidiary of Takeda, aims to acquire Multilab. Takeda expects...
The Actos Resource Center is the Web’s largest source for information on Actos research, side effects and legal news. Visit http://www.ActosCancer.com. Los Angeles, CA (PRWEB) May 11, 2012 The Actos Resource Center, a bladder cancer patient advocacy group, is alerting patients of the risks of bladder cancer from Actos after new research in the journal Neuropsychopharmacology indicated the drug may be beneficial in treating depression. Actos, a popular treatment for type II diabetes, has...
The Consumer Justice Foundation, a for-profit corporation whose Web site URL can be found at http://www.sideeffectsrx.com, is a team of consumer advocates who provide free online educational resources that are designed to inform consumers regarding the potential risks regarding the use of certain prescription medications. The CJF hereby reports that another Actos side effects lawsuit has been filed, and this individual claim will become part of the MDL, or multi-district litigation, that...
PHILADELPHIA, May 8, 2012 /PRNewswire/ -- Today, H. Lundbeck A/S (Lundbeck) and Takeda Pharmaceutical Global Research & Development Center Inc., U.S., presented data which demonstrated significant improvements in overall symptoms of depression in elderly patients taking Lu AA21004, an investigational compound for the treatment of major depressive disorder (MDD). This study was presented at the 2012 American Psychiatric Association (APA) Annual Meeting in Philadelphia....
DEERFIELD, Ill., May 2, 2012 /PRNewswire/ -- Celebrity chef Spike Mendelsohn knows all too well the effects of a busy and hectic lifestyle - especially for a person with acid reflux disease (ARD). But while he's used to firing up the grill, Chef Spike has also had to learn how to turn down the heat on his heartburn associated with ARD. To raise awareness and understanding about the importance of managing heartburn symptoms of ARD, including through lifestyle modifications,( )Chef...
The Actos Resource Center is the Web’s largest source for information on Actos research, side effects and legal news. Visit http://www.ActosCancer.com (PRWEB) April 27, 2012 The Actos Resource Center, a consumer advocacy group, is alerting patients in the United States of an additional warning issued over the safety of Actos by Canada’s top drug regulatory agency. Health Canada issued a warning on April 19, 2012 that the diabetes drug Actos may cause an increased risk of bladder...
DEERFIELD, Ill. and OSAKA, Japan, April 25, 2012 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced that the company received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone. Recently, Takeda provided...
